Within the enthesopathy treatment market, application segmentation delineates therapeutic use across distinct anatomical sites. The primary application categories include plantar fasciitis, Achilles tendinopathy, rotator cuff enthesopathy, patellar tendon enthesopathy, and miscellaneous sites grouped as “Other.” Each category reflects a unique pathophysiological profile, influencing drug delivery routes, dosage forms, and clinical trial designs. Plantar fasciitis accounts for roughly 30 % of total market revenue due to its high prevalence in both athletic and sedentary populations, driving extensive demand for injectable corticosteroids and biologics. Achilles tendinopathy contributes approximately 25 %, supported by growing interest in regenerative therapies such as platelet‑rich plasma. Rotator cuff enthesopathy, representing 20 % of the market, is propelled by an aging demographic and increasing shoulder‑injury surgeries. Patellar tendon enthesopathy, at 15 %, benefits from orthopedic sports‑medicine adoption. The residual 10 % classified as “Other” aggregates less common sites, yet collectively sustains niche product pipelines. This application‑focused taxonomy clarifies how each sub‑segment adds to overall market size, a core element of enthesopathy treatment segmentation.
